Opportunity
Federal Register #FDA-2025-N-2699
FDA proposal on N-acetyl-L-cysteine in dietary supplements
Buyer
Food and Drug Administration
Posted
November 17, 2026
Respond By
January 20, 2027
Identifier
FDA-2025-N-2699
The U.S. Food and Drug Administration is proposing a regulatory change concerning N-acetyl-L-cysteine (NAC), not seeking goods or services. - Government agency: U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA). - Proposal: FDA proposes that NAC is not excluded from the dietary supplement definition under the Federal Food, Drug, and Cosmetic Act. - If finalized, otherwise compliant NAC-containing products could be marketed as dietary supplements. - FDA also proposes that adding NAC to a dietary supplement would not be a prohibited act under section 301(ll) of the Act. - Procurement status: This is a regulatory rulemaking, not a procurement opportunity. No products, services, quantities, part numbers, OEMs, or vendors are solicited or identified.
Description
The FDA proposes a regulation finding that N-acetyl-L-cysteine (NAC) is not excluded from the dietary supplement definition under the Federal Food, Drug, and Cosmetic Act. If finalized, products containing NAC could be marketed as dietary supplements, provided they otherwise comply with the Act. FDA also proposes that adding NAC to a dietary supplement would not be a prohibited act under section 301(ll) of the Act. Comments are due January 19, 2027.